SCP
VRTX icon

Sandhill Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Sandhill Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-163,114
Closed -$32.9M – 100
2021
Q2 		$32.9M Sell
163,114
-21,061
-11% -$4.41M 2.57% 24
2021
Q1 		$39.6M Buy
+184,175
New +$40.5M 3.36% 12

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sandhill Capital Partners's VRTX Position: Q3 2021 in Review

Sandhill Capital Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 163,114 shares — an estimated $32.9M sold.

Sandhill Capital Partners first reported a position in VRTX in Q1 2021 and held it in 2 quarters. The position peaked at $39.6M in Q1 2021. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Sandhill Capital Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Sandhill Capital Partners sold 163,114 Vertex Pharmaceuticals shares in Q3 2021, an estimated $32.9M.
  • Sandhill Capital Partners first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Sandhill Capital Partners's Vertex Pharmaceuticals position peaked at $39.6M in Q1 2021.
  • 933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Sandhill Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.